Latest news with #equityfinancing
Yahoo
08-07-2025
- Business
- Yahoo
ZhongAn Online raises HK$3.92bn in post-IPO equity financing
China-based ZhongAn Online P & C Insurance has completed its H share placement, raising gross proceeds of approximately HK$3.92bn ($500m). The transaction marks the first instance of equity financing for the company since its initial public offering in 2017. The placement involved the issuance of 215 million new H shares at a price of HK$18.25 per share, accounting for nearly 12.76% of the its enlarged share capital following the placement. The net proceeds from this equity financing are intended to drive the company's business development initiatives. Specifically, 60% of the funds will be allocated to the company's core insurance underwriting and asset management operations, with another 30% for investment in fintech innovations. The remaining 10% will be directed towards general corporate purposes. ZhongAn board of directors stated: "This successful placement is a transformative step in ZhongAn's evolution. The capital infusion empowers our dual-engine strategy—driving core insurance growth while scaling technology-driven solutions. 'Through disciplined deployment, we will further unlock synergies at the intersection of finance and technology, delivering sustainable value to stakeholders." ZhongAn is recognized as an "internet-based" InsurTech company in China, employing a "Insurance + Technology" strategy, enhancing its underwriting, distribution, and customer service capabilities. It was established in 2013, and subsequently listed on the Hong Kong Stock Exchange in 2017. As of mid-2023, ZhongAn has reportedly served over 500 million users and issued approximately 57.4 billion insurance policies. Additionally, the company operates in Southeast Asia, East Asia, and Europe, and spanning sectors such as banking, insurance, securities, high-end manufacturing, and Internet platforms. "ZhongAn Online raises HK$3.92bn in post-IPO equity financing " was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
24-06-2025
- Business
- Yahoo
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request to withdraw the related resale registration statement with the SEC HOUSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the 'Company'), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces a comprehensive restructuring of its previous $15 million equity financing announced on March 4, 2025. This strategic restructuring eliminates potential dilution of up to 1.5 billion shares of common stock, which the Company believes will significantly enhance shareholder value and position the Company to move forward with a more straightforward equity capital structure. KEY HIGHLIGHTS OF THE EQUITY FINANCING RESTRUCTURING Elimination of Dilutive Warrants: The restructuring cancels warrants associated with the equity financing, which could have resulted in the issuance of up to 1.51 billion shares of common stock, leaving approximately 36 million shares of common stock issuable upon exercise of amended Series B Warrants at an alternative cashless exercise ratio of 1:1 Cancellation of Common Stock and Pre-Funded Warrants (PFWs): The restructuring will lead to the cancellation of approximately 25 million shares of common stock (or PFWs in lieu), further reducing stockholder dilution Future Financing Provisions: The Company will use 90% of future proceeds from any capital raised subsequent to July 1, 2025 to repay the holders of 22,727,270 shares of common stock (or PFWs in lieu) at 115% of the price originally paid for such securities in the March 2025 Equity Financing, based on an effective initial price of $0.66 per share Plus Therapeutics has also filed a request with the U.S. Securities and Exchange Commission (the 'SEC') to withdraw the resale registration statement related to the March 2025 Equity Financing. The Company would like to thank all parties involved in the transaction for their contribution to completing this fundamental restructuring. For more information, please refer to the Current Report on Form 8-K filed with the SEC on June 17, 2025, which can be found here. About Plus TherapeuticsHeadquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit Forward-Looking Statements This press release contains statements that may be deemed 'forward-looking statements' within the meaning of U.S. securities laws, including statements regarding potential dilution of the March 2025 Equity Financing, the impact that the restructuring referred to herein will have on shareholder value and the Company's equity capital structure, clinical outcomes, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as 'expect' 'potential,' 'anticipating,' 'planning' and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the Company's ability to maintain the listing of its common stock on Nasdaq; risks related to a halt in trading or delisting of the Company's common stock on Nasdaq; risks related to the realization by shareholders of anticipated value from the restructuring referred to herein, as well as general market perception of the restructuring, the early stage of the Company's product candidates and therapies; the results of the Company's research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's liquidity and capital resources and its ability to raise additional cash; the outcome of the Company's partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company's clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company's operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics' business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics' annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC's website at Any or all forward-looking statements Plus Therapeutics makes may turn out to be incorrect and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so. Investor ContactCORE IRinvestor@ 1 Metric based on the maximum dilutive impact of the March 2025 Equity Financing, as of March 4, 2025, the closing date of such transaction, which assumes (i) a Reset Price equal to the Floor Price in each of the Series A Warrants and Series B Warrants, and (ii) use of the 'alternative cashless exercise' feature in the Series B Warrants at a ratio of 3:1 at the time of exercise by the holders in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
Aya Gold & Silver Announces Filing of Prospectus Supplement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. The base shelf prospectus and the prospectus supplement are accessible on SEDAR+. Any amendment to the foregoing documents will be accessible within one business day on SEDAR+. MONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) ('Aya' or the 'Company') is pleased to announce that it has filed a prospectus supplement (the 'Supplement') to its short form base shelf prospectus dated June 10, 2025 (the 'Base Prospectus') with respect to its previously announced bought deal equity financing to purchase, on a bought deal basis, 9,363,300 common shares in the capital of the Company (the 'Shares'), at a price of $13.35 per Share (the 'Issue Price') for gross proceeds of $125,000,055 (the 'Offering'). The Supplement has been filed with the securities regulatory authorities in each of the provinces of Canada. The Offering is led by Desjardins Capital Markets ('Desjardins'), as sole bookrunner, together with a syndicate of underwriters including National Bank Financial Inc. and BMO Capital Markets, together with Desjardins as co-lead underwriters (collectively, the 'Underwriters'). The Company has granted the Underwriters an over-allotment option to purchase up to an additional 15% of the Shares at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering (the 'Over-Allotment Option'). If the Over-Allotment Option is exercised in full, $18,750,008 additional proceeds will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be approximately $143,750,063. The Company intends to use the net proceeds of the Offering to advance its business objectives including for the advancement of its exploration program at Boumadine, the exploration program at Zgounder Regional, and for working capital and general corporate purposes. The closing date of the Offering is scheduled to be on or about June 18, 2025, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Toronto Stock Exchange and the applicable securities regulatory authorities. Access to the Supplement, the corresponding Base Prospectus and any amendment thereto are provided in accordance with securities legislation relating to procedures for providing access to a base shelf prospectus, a prospectus supplement and any amendment thereto. The Supplement and the corresponding Base Prospectus are, and any amendment thereto, if any, will be, accessible on SEDAR+ at Electronic or paper copies of the Base Prospectus, the Supplement, and any amendment to the foregoing documents may be obtained, without charge, from Desjardins at 25 York St., 10th Floor, Toronto, ON M5J 2V5, Attention: Equity Capital Markets or by email at ecm@ by providing Desjardins with an email address or address, as applicable. The Supplement, the corresponding Base Prospectus and any amendment thereto contain important detailed information about the Company and the Offering. Prospective investors should read the Supplement, the corresponding Base Prospectus and the other documents the Company has filed on SEDAR+ before making an investment decision. This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the '1933 Act'), and may not be offered or sold in the United States absent registration under the 1933 Act and all applicable U.S. state securities laws, or in compliance with applicable exemptions from such registration requirements. AYA GOLD & SILVER 'Benoit La Salle' Benoit La Salle, FCPA FCAPresident and Chief Executive Officer About Aya Gold & Silver Inc. Aya Gold & Silver Inc. is a rapidly growing, Canada-based silver producer with operations in the Kingdom of Morocco. The only TSX-listed pure silver mining company, Aya operates the high-grade Zgounder Silver Mine and is exploring its properties along the prospective South-Atlas Fault, several of which have hosted past-producing mines and historical resources. Aya's management team has been focused on maximising shareholder value by anchoring sustainability at the heart of its operations, governance, and financial growth plans. For additional information, please visit Aya's website at Or contact Benoit La Salle, FCPA FCAPresident & CEO Alex Ball VP, Corporate Development & IR Notice Regarding Forward Looking Information Certain information in this news release related to the Company is forward-looking information and is prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events, and is therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking information. The information generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking information in this news release include statements regarding the Offering including anticipated timing of closing, the exercise of the Over-Allotment Option, the receipt of required regulatory approvals including acceptance of the Offering by the TSX, and the intended use of proceeds of the Offering. There are numerous risks and uncertainties that could cause actual results and Aya's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks inherent in the mineral production and exploration sectors in general; (iii) that the proceeds of the Offering may need to be used other than as set out in this news release, as well as other risks and uncertainties which are more fully described in Aya's 2024 Annual Information Form dated March 31, 2025, and in other filings of Aya with securities and regulatory authorities which are available on SEDAR+ at Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward‐looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward‐looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward‐looking information. Such forward‐looking information has been provided for the purpose of assisting investors in understanding the Company's business, operations and exploration plans and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward‐looking information. Forward‐looking information is given as of the date of this news release, and the Company does not undertake to update such forward‐looking information except in accordance with applicable securities laws.
Associated Press
10-06-2025
- Business
- Associated Press
Arvana Inc. Announces $100 Million Financing Initiative to Support Strategic Acquisitions by PintoCity Inc.
LAS VEGAS, NEVADA / ACCESS Newswire / June 10, 2025 / Arvana Inc. (OTC PINK:AVNI) is pleased to announce that it is undertaking both debt and equity financing initiatives to support acquisitions and development activities by its strategic partner, PintoCity Inc. PintoCity is a privately held company, under an MOU to be a fully owned subsidiary of Arvana, that is focused on the transformation and redevelopment of underutilized retail assets. Its business model centers on acquiring and managing vacant shopping centers and big box retail stores across the United States. These properties will be repurposed into entertainment and themed destinations, supported by a revenue-generating strategy designed to revitalize communities and create shareholder value. Arvana has presented a $100 million financing proposal in two (2) tranches of $50M each to prospective lenders and equity investors. As of this announcement, two Letters of Intent (LOIs) have been received from a single lender for $7 million. Negotiations are currently underway for this and additional funding commitments. To complement the debt financing, Arvana is also offering a private placement of 5 million shares to accredited investors/lenders. About Arvana Inc. Arvana Inc. (OTC: AVNI) is a publicly traded company registered under the Securities Exchange Act of 1934, as amended, and is listed on the OTC Pink Sheets with Current Information status under the Alternative Reporting Standard. Bondock LLC, the controlling stockholder of Arvana owns PintoCity. More information can be found at Additional Information: Forward-Looking Statements Several statements contained in this press release are forward-looking statements of future expectations based on currently available information that are subject to risks and uncertainties including general economic conditions, changes in capital markets, regulator legislation, and other circumstances that may cause actual results to be materially different from those expectations Arvana does not make any representation or warranty, express or implied, as to the accuracy, completeness, or status of such statements so it will not be liable for any decision made or action taken in conjunction with the information and/or statements contained in this press release. Arvana encourages the public to read the information provided in conjunction with its recent filings on Form 8-K, Form 10-Q and Form 10-K, which may be viewed at SOURCE: Arvana, Inc. press release
Yahoo
17-05-2025
- Business
- Yahoo
Advanced Micro Devices (NasdaqGS:AMD) Stockholders Approve Increase in Authorized Shares
Advanced Micro Devices has successfully amended its corporate bylaws to significantly increase its authorized shares, a move that could provide greater flexibility for future equity financing and initiatives. Over the past month, the company's stock has risen by 34%, a performance substantially outpacing the broader market's 5% gain. This price move is likely bolstered by the combination of strong earnings growth, an expanded buyback program, and pivotal partnerships in AI infrastructure, which together have positioned AMD favorably compared to market trends. The broader corporate developments certainly added weight to the momentum behind this price movement. Buy, Hold or Sell Advanced Micro Devices? View our complete analysis and fair value estimate and you decide. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent amendment to Advanced Micro Devices' bylaws, aimed at increasing authorized shares, introduces greater flexibility for future equity initiatives. This regulatory maneuver could play a crucial role amidst challenges from deglobalization and export controls which threaten AMD's access to pivotal markets. Over a five-year span, AMD has delivered a substantial total return of 112.38%, reflecting its capability to adapt and pivot within the volatile semiconductor landscape, although the past year's performance lagged behind the broader semiconductor industry's 22.9% return. Potential changes from this share authorization could impact revenue and earnings forecasts as they align with ongoing AI and innovation-driven demand. There are risks from competitive pressures and evolving supply chain dynamics that could compress margins and add volatility to earnings. Despite these hurdles, the company has set a target of US$127.19, with its current share price of US$98.62 reflecting an 8.55% discount to this target, suggesting potential upside if challenges are effectively managed and market conditions remain favorable. Balancing authorized share issuance with operational advancements might calibrate AMD's approach to navigate both growth and risk scenarios effectively. Our comprehensive valuation report raises the possibility that Advanced Micro Devices is priced higher than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:AMD. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
